Ipilimumab-induced cutaneous reactions.

*case is detailed in the result section.alisted treatments are systemic treatments unless otherwise specified.btumor free high-risk stage III melanoma (AJCC 2009); adjuvant administration of ipilimumab.cstage IV metastatic disease (AJCC 2009).dMelanA-specific vaccination.M indicates male; F, female; LN, lymph nodes; IFN-α, interferon-α; DTIC, dacarbazine; TKI, tyrosine kinase inhibitor; PR, partial response; SD, stable disease; PD, progressive disease; MR, mixed response; CR, complete response; MAH, melanoma-associated hypopigmentation.

*病例详情参见结果章节。
a. 除非另有说明，所列治疗方式均为系统性治疗。
b. 高危无瘤Ⅲ期黑色素瘤（AJCC 2009版分期）；伊匹木单抗辅助给药。
c. Ⅳ期转移性疾病（AJCC 2009版分期）。
d. MelanA特异性疫苗接种。
M代表男性（male）；F代表女性（female）；LN代表淋巴结（lymph nodes）；IFN-α代表干扰素-α（interferon-α）；DTIC代表达卡巴嗪（dacarbazine）；TKI代表酪氨酸激酶抑制剂（tyrosine kinase inhibitor）；PR代表部分缓解（partial response）；SD代表疾病稳定（stable disease）；PD代表疾病进展（progressive disease）；MR代表混合缓解（mixed response）；CR代表完全缓解（complete response）；MAH代表黑色素瘤相关性色素减退（melanoma-associated hypopigmentation）。